Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study' by Potere et al' by Buckley
Nicola Potere, Marcello Di Nisio, Donatella Concetta Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti
Topics & Concepts
TocilizumabMedicineMechanical ventilationPneumoniaCytokine release syndromeMethylprednisoloneBlockadeDexamethasoneAnesthesiaCoronavirus disease 2019 (COVID-19)Interleukin 6Cytokine stormGastroenterologyInternal medicineCytokineReceptorRheumatoid arthritisInfectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Respiratory Support and Mechanisms